In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity

M. F. Sarosdy, D. H. Hutzler, D. Yee, D. D. Von Hoff

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

TP-40 is a hybrid fusion protein produced by recombinant technology and consists of a molecule of transforming growth factor-alpha (TGF-alpha) fused to the Pseudomonas exotoxin PE-40. A panel of human and murine bladder cancer cell lines was found to be universally sensitive in vitro to TP-40 in a clonogenic assay. All lines expressed receptor for epidermal growth factor (EGF), though none demonstrated gene amplification for the EGF receptor. The sensitivity to TP-40 may be blocked by preexposure to EGF. Six human bladder tumors taken directly from patients were all sensitive in vitro to TP-40; these included well-differentiated tumors. TP-40 may prove to be effective as an intravesical agent in bladder cancer via selective targeting to cells that express EGF receptors, as do the majority of human bladder cancers.

Original languageEnglish (US)
Pages (from-to)1950-1955
Number of pages6
JournalJournal of Urology
Volume150
Issue number6
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Keywords

  • bladder neoplasms
  • cytotoxicity
  • immunologic

Fingerprint

Dive into the research topics of 'In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity'. Together they form a unique fingerprint.

Cite this